Semaglutide (GLP1S)
For Research Use Only
Injectable
A GLP-1 receptor agonist peptide studied in pharmacology and metabolic research models. Published literature examines glucagon-like peptide-1 receptor binding, incretin signaling, and glucose homeostasis pathways in experimental systems. Laboratory research areas include: receptor pharmacology, metabolic pathway modeling, and preclinical pharmacology.
Size: 20mg
$350.00
In stockCheckout opens once payment is connected.
Certificates of analysis
No certificate has been published for this product yet.
Research guides
- Semaglutide and the GLP-1 Receptor: What the Published Research ReportsA research-framed overview of the published literature on semaglutide, covering its molecular design and GLP-1 receptor affinity in preclinical characterisation work, mechanistic hypotheses from preclinical and clinical reviews, and reported outcomes in human trials, cohort studies, and pharmacovigilance datasets.
- Semaglutide and the GLP-1 Receptor: What Binding and Receptor-Engagement Assays ReportA research-library survey of published structural, radioligand competition, cell-based signalling, and albumin-binding assay work in which semaglutide was characterised or used as a comparator at the GLP-1 receptor, with the model system (in vitro, animal, or human) stated for each finding.
- Semaglutide: What the Published Studies ReportA research-framed survey of the published semaglutide literature, covering head-to-head human trials in type 2 diabetes and obesity, combination and real-world cohort data, reported adverse-event patterns, and preclinical rodent work on alcohol-related behaviour.
This product is not for human or animal consumption. Misuse of this product is illegal.